DEC-205/NY-ESO-1 Fusion Protein CDX-1401

BIOLOGICAL6 trials

Sponsors

Roswell Park Cancer Institute, National Cancer Institute (NCI)

Conditions

Acute Myeloid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaAnaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaBlasts 30 Percent or Less of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaCutaneous Melanoma

Phase 1

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

CompletedNCT01522820

Roswell Park Cancer InstituteAnaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma +62

Start: 2012-03-31End: 2016-07-31Updated: 2016-10-04

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

CompletedNCT01834248

Roswell Park Cancer InstituteAcute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia +2

Start: 2013-07-30End: 2016-03-21Updated: 2022-07-22

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

CompletedNCT02166905

Roswell Park Cancer InstituteFallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma

Start: 2014-10-10End: 2020-08-20Updated: 2023-02-24

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT03206047

National Cancer Institute (NCI)Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +3

Start: 2017-11-08End: 2020-11-10Updated: 2025-03-13

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

CompletedNCT03358719

Roswell Park Cancer InstituteAcute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia +3

Start: 2018-03-27End: 2021-08-25Updated: 2026-02-27

Phase 2

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

CompletedNCT02129075

National Cancer Institute (NCI)Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary +9

Start: 2014-04-09End: 2018-05-18Updated: 2021-11-16

Related Papers

Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4<sup>+</sup> T cells in MDS.

2025-04-25

mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors

Journal for ImmunoTherapy of Cancer2025-03-015 citations

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.

2020-11-1688 citations

A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.

Journal of Clinical Oncology2016-05-2019 citations